Overview
International law firm McDermott Will & Emery represented Applied DNA Sciences, Inc. (Applied DNA), a leader in PCR-based DNA technologies, in its $12 million public offering.
The offering is comprised of 9,230,769 Units with each Unit consisting of one share of common stock (or pre-funded warrant), one Series A Warrant to purchase one share of common stock exercisable on the date of stockholder approval and expiring on the fifth anniversary thereof, and one Series B Warrant to purchase one share of common stock exercisable on the date of stockholder approval and expiring one year from the date thereof or, pursuant to an alternative cashless exercise option, the right to receive three shares of common stock.
The McDermott team was led by Merrill M. Kraines and Todd Kornfeld and included Brandon Sloane.
Read Applied DNA’s announcement here.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
